Abstract:Rationale: Inflammatory bowel diseases (IBDs) are still awaiting innovative treatments that can maximize the efficiency of site-specific drug release in the colon while enhancing intestinal homeostasis. Methods: Herein, we present multilayer-coated mesoporous silica (MSs) which release payload drugs specifically in the colon tract in the presence of azoreductase produced by the gut microbiota, and simultaneously rejuvenate the tryptophan metabolism of the microbiome to induce activation of the aryl hydrocarbon receptor (AHR) for increased anti-inflammatory effects. The MSs were prepared by using cucurbit[8]uril (CB[8]) as a supramolecular "handcuff" to assemble chitosan/hyaluronic acid multilayers on the periphery of a mesoporous silica core. Results: Strikingly, although MSs remained fairly stable in both acidic and neutral pH, they exhibited excellent responsiveness towards dithionite, an azo-reducing agent employed as a substitute to mimic the specific azoreductase environment in vitro. In comparison with the drug in its free form, hydrocortisone-loaded MSs showed optimized accumulation of therapeutics in the colonic mucosa with minimized premature release in the upper gastrointestinal tract in in vivo imaging and biodistribution studies. The enhanced therapeutic effects of MSs were confirmed in dextran sodium sulfate-induced colitis in mice with promoted colonic epithelial barrier integrity, elevated level of AHR agonists and modulated production of inflammatory cytokines. Furthermore, 16S rRNA analysis showed that the disrupted gut homeostasis of colitic mice was partly corrected by MSs. Conclusion: This novel drug delivery system using self-assembly of tryptophan-functionalized chitosan, which was precomplexed with CB[8], and azobenzene-functionalized hyaluronic acid on the surface of mesoporous silica nanoparticles provides a synergistic gut microbiota-targeting approach for IBD therapy.

Investigation of Cucurbit(7)Uril As A 5-Aminosalicylic Acid Colon-Specific Drug Delivery

SYNTHESIS AND IN VITRO BIODEGRADATION OF AZO POLYMER FOR COLON-SPECIFIC DRUG DELIVERY

Degradability of the Linear Azo Polymer Conjugated 5,5′‐azodisalicylic Acid Segment in the Main Chain for Colon‐specific Drug Delivery

Exploring the Effect of Different Linkers on Self-Assembly, ROS-sensitivity and Anticancer Efficacy of Hydroxyethyl Starch-Curcumin Prodrug

Preparation of Cucurbit[5]uril - Ln3+ - Based Supramolecular Assemblies and Its Effective Detection of L-Tryptophan

5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis

A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis

Preparation and in vitro release of 5-aminosalicylic acid time-controlled release pellets for colon-specific delivery

pH and redox dual response nano-suppository for the treatment of ulcerative colitis

Eudragit S100 coated iron oxide-chitosan nanocomposites for colon targeting of 5-aminosalicylic acid ameliorate ulcerative colitis by improving intestinal barrier function and inhibiting NLRP3 inflammasome

Orally administered mesoporous silica capped with the cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota

Application of inulin/Eudragit RS in 5-ASA pellet coating with tuned, sustained-release feature in an animal model of ulcerative colitis

Sustained release of 5-aminosalicylic acid from azoreductase-responsive polymeric prodrugs for prolonged colon-targeted colitis therapy

Construction of a ratio fluorescence assay of 5-aminosalicylic acid based on its aggregation induced emission with blue emitting N/P-codoped carbon dots

Preferential binding of cucurbit[7]uril toward 2-amino-4-chlorophenol in chlorzoxazone

Isoliquiritigenin containing pH sensitive micelles for enhanced anti-colitis activity

Nanofiber-boosted retrograded starch/pectin microparticles for targeted 5-Aminosalicylic acid delivery in inflammatory bowel disease: In vitro and in vivo non-toxicity evaluation

Improving Drug Utilization Platform with Injectable Mucoadhesive Hydrogel for Treating Ulcerative Colitis

Oral formulation of 5-aminosalicylic acid-Hemoglobin bio-adhesive nanoparticles enhance therapeutic efficiency in Ulcerative Colitis mice: A preclinical evaluation

5-Aminosalicylic Acid Loaded Chitosan-Carrageenan Hydrogel Beads with Potential Application for the Treatment of Inflammatory Bowel Disease

Selective pharmaceutical sensitization design based on amino acid metabolism: 5-fluorouracil-sarcosine cocrystal prepared by wet powder grinding method